Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Hum Mol Genet. 2013 Nov 15;22(22):4638-45. doi: 10.1093/hmg/ddt312. Epub 2013 Jul 10.
We describe two unreported types of congenital disorders of glycosylation (CDG) which are caused by mutations in different isoforms of the catalytic subunit of the oligosaccharyltransferase (OST). Each isoform is encoded by a different gene (STT3A or STT3B), resides in a different OST complex and has distinct donor and acceptor substrate specificities with partially overlapping functions in N-glycosylation. The two cases from unrelated consanguineous families both show neurologic abnormalities, hypotonia, intellectual disability, failure to thrive and feeding problems. A homozygous mutation (c.1877T > C) in STT3A causes a p.Val626Ala change and a homozygous intronic mutation (c.1539 + 20G > T) in STT3B causes the other disorder. Both mutations impair glycosylation of a GFP biomarker and are rescued with the corresponding cDNA. Glycosylation of STT3A- and STT3B-specific acceptors is decreased in fibroblasts carrying the corresponding mutated gene and expression of the STT3A (p.Val626Ala) allele in STT3A-deficient HeLa cells does not rescue glycosylation. No additional cases were found in our collection or in reviewing various databases. The STT3A mutation significantly impairs glycosylation of the biomarker transferrin, but the STT3B mutation only slightly affects its glycosylation. Additional cases of STT3B-CDG may be missed by transferrin analysis and will require exome or genome sequencing.
我们描述了两种未报道的先天性糖基化障碍(CDG)类型,它们是由寡糖基转移酶(OST)的催化亚基的不同同工型的突变引起的。每个同工型由不同的基因(STT3A 或 STT3B)编码,位于不同的 OST 复合物中,具有不同的供体和受体底物特异性,在 N-糖基化中具有部分重叠的功能。这两个来自无血缘关系的近亲家庭的病例均表现出神经异常、张力减退、智力残疾、生长不良和喂养问题。STT3A 中的纯合突变(c.1877T > C)导致 p.Val626Ala 变化,而 STT3B 中的纯合内含子突变(c.1539 + 20G > T)导致另一种疾病。这两种突变均损害 GFP 生物标志物的糖基化,并用相应的 cDNA 进行挽救。携带相应突变基因的成纤维细胞中 STT3A 和 STT3B 特异性受体的糖基化减少,而在 STT3A 缺陷的 HeLa 细胞中表达 STT3A(p.Val626Ala)等位基因不能挽救糖基化。在我们的研究中或在审查各种数据库时均未发现其他病例。STT3A 突变显著损害了生物标志物转铁蛋白的糖基化,但 STT3B 突变仅略微影响其糖基化。STT3B-CDG 的其他病例可能会因转铁蛋白分析而被遗漏,并且需要外显子或基因组测序。